Trogenix

Trogenix is a pioneering biotech company dedicated to developing innovative cancer therapies. Calculus invested £1million as part of its Series A financing, raising £70 million. The funding will enable the rapid advancement of its robust pipeline of potentially curative cancer therapies across multiple aggressive solid tumours into the clinic.

Trogenix is revolutionising cancer treatment by combining the dual power of cancer cell killing and immune stimulation, delivered via a Trojan Horse approach that reawakens the immune system to provide long-term protection against tumour recurrence. Playing a central role to Trogenix’s precision cancer treatments are its proprietary Synthetic Super Enhancers (SSEs) which are activated by targeting the unique identity of diseased cell states, rather than individual genes, to control two key payloads: a cytotoxic prodrug converting enzyme and an immune stimulating cytokine. SSEs are exquisitely designed using Trogenix’s proprietary technology platform, Odysseus®, which rigorously identifies and optimises targets in cancer cells to rapidly generate candidates with manufacturable profiles for preclinical development.

Rationale

Trogenix’s lead programme, in glioblastoma multiforme (GBM), one of the most aggressive and treatment-resistant brain cancers, is advancing toward clinical trials with first patient dosing anticipated in Q1 2026. Only 25% of GBM patients survive beyond one year1 and despite decades of research and significant investment, treatment options remain severely limited. The Company’s follow-on programme is in colorectal cancer liver metastases (CRCLM). Colorectal cancer is the third most common cancer worldwide2, with at least 25% of patients developing CRCLM3.
In addition to its lead and follow-on programmes, Trogenix will be developing its pipeline focused on other aggressive solid cancers including hepatocellular carcinoma and non-small cell lung carcinoma.